Naringin enhances reverse cholesterol transport in high fat/low streptozocin induced diabetic rats

Biomedicine and Pharmacotherapy

Volumn 101, Issue , 2018, Pages 430-437

  Rotimi, Solomon Oladapo ^a   Adelani, Isaacson Bababode ^a   Bankole, Goodness Esther ^a   Rotimi, Oluwakemi Anuoluwapo ^a  

^a Centre for Economic Policy and Development Research   (Nigeria)

Author keywords

Antioxidant; Diabetes mellitus; Gene expression; Lipid; Paraoxonase

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; ARYLDIALKYLPHOSPHATASE; AURANTIIN; BETA ACTIN; CHOLESTEROL; HEPATIC LIPASE C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIVER TRIACYLGLYCEROL LIPASE; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SCAVENGER RECEPTOR B; SCAVENGER RECEPTOR CLASS B MEMBER 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; ANTIOXIDANT; BIOLOGICAL MARKER; FLAVANONE DERIVATIVE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETES CONTROL; DRUG MECHANISM; ENZYME ACTIVITY; GENE EXPRESSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; HYPERGLYCEMIA; LIPID DIET; LIVER; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL TRANSPORT; BIOMARKERS; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; FLAVANONES; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; LIVER; MALE; RATS; STREPTOZOCIN; TRIGLYCERIDES;

EID: 85042632301     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2018.02.116     Document Type: Article

References (41)

1. Sharma, M., Nazareth, I., Petersen, I., Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study. BMJ Open, 6(1), 2016, e010210.
2. Grundy, S.M., Benjamin, I.J., Burke, G.L., Chait, A., Eckel, R.H., Howard, B.V., Mitch, W., Smith, S.C. Jr., Sowers, J.R., Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100:10 (1999), 1134–1146.
3. Hu, F.B., Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 34:6 (2011), 1249–1257.
4. Grundy, S.M., Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am. J. Cardiol. 81:4A (1998), 18B–25B.
5. Durrington, P.N., Mackness, B., Mackness, M.I., Paraoxonase and atherosclerosis. Arter. Thromb. Vasc. Biol. 21:4 (2001), 473–480.
6. Patra, S.K., Singh, K., Singh, R., Paraoxonase 1: a better atherosclerotic risk predictor than HDL in type 2 diabetes mellitus. Diabetes Metab. Syndr. 7:2 (2013), 108–111.
7. Rotimi, S.O., Olayiwola, I., Ademuyiwa, O., Adamson, I., Inability of legumes to reverse diabetic-induced nephropathy in rats despite improvement in blood glucose and antioxidant status. J. Med. Food 13:1 (2010), 163–169.
8. DeFronzo, R.A., Pharmacologic therapy for type 2 diabetes mellitus. Ann. Intern. Med. 133:1 (2000), 73–74.
9. Aruoma, O.I., Landes, B., Ramful-Baboolall, D., Bourdon, E., Neergheen-Bhujun, V., Wagner, K.H., Bahorun, T., Functional benefits of citrus fruits in the management of diabetes. Prev. Med. 54:Suppl (2012), S12–S16.
10. Choi, M.S., Do, K.M., Park, Y.S., Jeon, S.M., Jeong, T.S., Lee, Y.K., Lee, M.K., Bok, S.H., Effect of naringin supplementation on cholesterol metabolism and antioxidant status in rats fed high cholesterol with different levels of vitamin E. Ann. Nutr. Metab. 45:5 (2001), 193–201.
11. Xulu, S., Oroma Owira, P.M., Naringin ameliorates atherogenic dyslipidemia but not hyperglycemia in rats with type 1 diabetes. J. Cardiovasc. Pharmacol. 59:2 (2012), 133–141.
12. Parmar, H.S., Jain, P., Chauhan, D.S., Bhinchar, M.K., Munjal, V., Yusuf, M., Choube, K., Tawani, A., Tiwari, V., Manivannan, E., Kumar, A., DPP-IV inhibitory potential of naringin: an in silico, in vitro and in vivo study. Diabetes Res. Clin. Pract. 97:1 (2012), 105–111.
13. Pari, L., Chandramohan, R., Modulatory effects of naringin on hepatic key enzymes of carbohydrate metabolism in high-fat diet/low-dose streptozotocin-induced diabetes in rats. Gen. Physiol. Biophys. 36:3 (2017), 343–352.
14. Zhang, M., Lv, X.Y., Li, J., Xu, Z.G., Chen, L., The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp. Diabetes Res., 2008, 2008, 704045.
15. Rotimi, S.O., Bankole, G.E., Adelani, I.B., Rotimi, O.A., Hesperidin prevents lipopolysaccharide-induced endotoxicity in rats. Immunopharmacol. Immunotoxicol., 2016, 1–8.
16. Rifai, N., Warnick, G.R., Dominiczak, M.H., Handbook of Lipoprotein Testing. 2000, Amer. Assoc. for Clinical Chemistry.
17. Rotimi, S.O., Ojo, D.A., Talabi, O.A., Balogun, E.A., Ademuyiwa, O., Tissue dyslipidemia in Salmonella-infected rats treated with amoxillin and pefloxacin. Lipids Health Dis., 11, 2012, 152.
18. Folch, J., Lees, M., Sloane Stanley, G.H., A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem., 226, 1957.
19. Rotimi, O.A., Olayiwola, I.O., Ademuyiwa, O., Balogun, E.A., Effects of fibre-enriched diets on tissue lipid profiles of MSG obese rats. Food Chem. Toxicol. 50:11 (2012), 4062–4067.
20. Afolabi, O.K., Wusu, A.D., Ogunrinola, O.O., Abam, E.O., Babayemi, D.O., Dosumu, O.A., Onunkwor, O.B., Balogun, E.A., Odukoya, O.O., Ademuyiwa, O., Paraoxonase 1 activity in subchronic low-level inorganic arsenic exposure through drinking water. Environ. Toxicol. 31:2 (2016), 154–162.
21. Ling, B., Aziz, C., Alcorn, J., Systematic evaluation of key L-carnitine homeostasis mechanisms during postnatal development in rat. Nutr. Metab., 9(1), 2012, 1.
22. Cushman, D., Cheung, H., Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem. Pharmacol. 20:7 (1971), 1637–1648.
23. Chaudhry, M.A., An exercise to estimate differential gene expression in human cells. Biochem. Mol. Biol. Educ. 34:2 (2006), 116–120.
24. Abràmoff, M.D., Magalhães, P.J., Ram, S.J., Image processing with ImageJ. Biophotonics Int. 11:7 (2004), 36–42.
25. Reed, M.J., Meszaros, K., Entes, L.J., Claypool, M.D., Pinkett, J.G., Gadbois, T.M., Reaven, G.M., A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metab. Clin. Exp. 49:11 (2000), 1390–1394.
26. Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C.L., Ramarao, P., Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 52:4 (2005), 313–320.
27. Tahara, A., Matsuyama-Yokono, A., Nakano, R., Someya, Y., Hayakawa, M., Shibasaki, M., Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. Pharmacol. Rep. PR 61:5 (2009), 899–908.
28. Drucker, D.J., Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes preclinical biology and mechanisms of action. Diabetes Care 30:6 (2007), 1335–1343.
29. Godinho, R., Mega, C., Teixeira-de-Lemos, E., Carvalho, E., Teixeira, F., Fernandes, R., Reis, F., The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a “Me Too” or “the special One” antidiabetic class?. J Diabetes Res., 2015, 2015, 806979.
30. Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Lerch, C., Dipeptidyl peptidase‐4 (DPP‐4) inhibitors for type 2 diabetes mellitus. Cochrane Lib., 16(2), 2008 CD006739.
31. Schrezenmeir, J., Hyperinsulinemia, hyperproinsulinemia and insulin resistance in the metabolic syndrome. Experientia 52:5 (1996), 426–432.
32. Linfoot, P., Bergstrom, C., Ipp, E., Pathophysiology of ketoacidosis in type 2 diabetes mellitus. Diabetic Med. 22:10 (2005), 1414–1419.
33. Murunga, A.N., Miruka, D.O., Driver, C., Nkomo, F.S., Cobongela, S.Z., Owira, P.M., Grapefruit derived flavonoid naringin improves ketoacidosis and lipid peroxidation in type 1 diabetes rat model. PloS One, 11(4), 2016, e0153241.
34. Arthur, M., Saum, L., Wilhoite, J.E., Hypertension management: making sense of guidelines and therapy options for the elderly. Indiana Pharm. Alliance Continuing Pharm. Educ., 2015, 1.
35. Guerrero, L., Castillo, J., Quiñones, M., Garcia-Vallvé, S., Arola, L., Pujadas, G., Muguerza, B., Inhibition of angiotensin-converting enzyme activity by flavonoids: structure-activity relationship studies. PLoS One, 7(11), 2012, e49493.
36. Zlobine, I., Gopal, K., Ussher, J.R., Lipotoxicity in obesity and diabetes-related cardiac dysfunction. Biochimica et Biophysica Acta (BBA)-Mol. Cell Biol. Lipids 1861:10 (2016), 1555–1568.
37. Lu, K.L., Xu, W.N., Wang, L.N., Zhang, D.D., Zhang, C.N., Liu, W.B., Hepatic beta-oxidation and regulation of carnitine palmitoyltransferase (CPT) I in blunt snout bream Megalobrama amblycephala fed a high fat diet. PLoS One, 9(3), 2014, e93135.
38. Tanos, R., Murray, I.A., Smith, P.B., Patterson, A., Perdew, G.H., Role of the Ah receptor in homeostatic control of fatty acid synthesis in the liver. Toxicol. Sci. 129:2 (2012), 372–379.
39. Tall, A.R., An overview of reverse cholesterol transport. Eur. Heart J. 19:Suppl. A (1998), A31–A35.
40. Larsson, S., Phytochemicals: aging and health. Ann. Bot., 104(7), 2009 ix.
41. Takaeidi, M.R., Jahangiri, A., Khodayar, M.J., Siahpoosh, A., Yaghooti, H., Rezaei, S., Salecheh, M., Mansourzadeh, Z., The effect of date seed (Phoenix dactylifera) extract on paraoxonase and arylesterase activities in hypercholesterolemic rats. Jundishapur J. Nat. Pharm. Prod. 9:1 (2014), 30–34.